Finance
Vital Signs reports 15% increase in annual income from continuing operations for FY 2006
Published in Healthcare Mergers, Acquisitions and Ventures Week, February 3rd, 2007
Diluted earnings per share from continuing operations increased 13% to $2.32 for the 12-month period ended September 30, 2006 compared to $2.06 for the 12-month period ended September 30, 2005.
Included in the 12-month results were $1,488,000 of costs for stock option compensation, now required to be expensed, effective for all reporting periods beginning October 1, 2005, under Financial Accounting Standard No. 123(R).
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Adverse Drug Reactions
Scientists at AstraZeneca detail research in adverse drug reactions in children - Alzheimer Disease
Allon receives approval for phase II clinical trial in Alzheimer-related condition - Analytical Chemistry
New analytical chemistry study findings have been reported from Merck & Co, Inc. - Angiogenesis
New angiogenesis study findings recently were published by researchers at ImClone Systems, Inc. - Animal Cloning
U.S. FDA issues draft documents on safety of animal clones - Anthrax Vaccines
Studies from Medarex, Inc. describe new findings in anthrax vaccines - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
